MediWound vs ProQR Therapeutics
MDWD and PRQR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDWD and PRQR compare
ProQR Therapeutics grew revenue faster over the last twelve months (11.4% versus −16.1% for MediWound).
ProQR Therapeutics scores higher on the StockData Score (6 against 2 for MediWound), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDWD | PRQR |
|---|---|---|
| Size and price | ||
| Share price | $12.97 | $1.41 |
| Change, 1 year | −30.0% | −34.7% |
| Change, 5 years | −35.4% | −81.9% |
| Beta (5Y) | 0.90 | 1.26 |
| Employees | 35 | 59 |
| StockData Score | ||
| Total score | 2 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −16.1% | 11.4% (better) |
| Revenue growth, 5Y average | −4.9% | – |
| Profitability | ||
| Gross margin | 19.2% | – |
| Operating margin | −149% (better) | −233% |
| Net margin | – | −229% |
| FCF margin | −128% (better) | −273% |
| Return on equity | – | −57.4% |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Interest coverage | −10.3× | – |
| Current ratio | 2.32 | 3.49 (better) |
| Piotroski F-score | – | 1 |
| Ownership | ||
| Held by institutions | 45.3% | 57.6% |
| Held by insiders | 23.4% | 37.8% |
| Insider net buying, 12 months | $60.6K | $1.3M (better) |
| Short interest, % of float | 18.2% | – |
Go deeper
- MDWD stock overview
- MDWD income statement
- MDWD valuation and score
- PRQR stock overview
- PRQR income statement
- PRQR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.